2018—2020年某院门诊药房口服降糖药用药分析

Oral hypoglycemic agents in outpatient pharmacy at some hospital from 2018 to 2020

目的了解和分析上海市松江区中心医院门诊口服降糖药用药趋势, 为临床合理用药提供参考。方法采用世界卫生组织推荐的限定日剂量(DDD)分析法, 回顾性分析上海市松江区中心医院2018—2020年门诊药房口服降糖药的销售金额、用药频度(DDDs)、限定日费用(DDC)等情况。结果 2018—2020年上海市松江区中心医院门诊口服降糖药销售金额位居前两位的是α-糖苷酶抑制剂和双胍类, 二肽基肽酶(DPP-4)抑制剂销售金额逐年上升;DDDs位居前三的始终是格列美脲、二甲双胍及阿卡波糖;二甲双胍和阿卡波糖DDC下降最为明显。结论α-糖苷酶抑制剂、双胍类和胰岛素促泌剂仍是上海市松江区中心医院临床一线治疗药物, 符合指南推荐, DPP-4抑制剂市场前景较大, 钠-葡萄糖协同转运蛋白2(SGLT-2)也将逐渐崭露头角。

Objective To investigate and analyze the trend of oral hypoglycemic drug use in the outpatient department of Shanghai Songjiang District Central Hospital,and to provide references for clinical rational drug use.Methods The consumption sum,DDDs,and defined daily cost(DDC)of the oral hypoglycemic drugs in the outpatient pharmacy of Songjiang District Central Hospital from 2018 to 2020 were analyzed retrospectively using the defined daily dose(DDD)analysis recommended by the World Health Organization.Results From 2018 to 2020,the oral hypoglycemic drugs with top two Sales amounts in Shanghai Songjiang District Central Hospital wereα-glycosidase inhibitors and biguanides,and the sales amount of dipeptidyl peptidase(DPP-4)inhibitors increased year by year.The drugs with top three DDDs were glimepiride,metformin,and acarbose.Metformin and acarbose showed the most significant decrease in DDC.Conclusionsα-glycosidase inhibition,biguanides,and insulin secreting agents are still the first-line treatment drugs in Songjiang District Central Hospital,which meet the recommendation of guidelines.DPP-4 inhibitors have a great market prospect,and odium-dependent glucose transporters 2(SGLT-2)will gradually emerge.